跳至主要内容
临床试验/NCT07670520
NCT07670520招募中不适用

Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial

Mayo Clinic3 个研究点 分布在 1 个国家目标入组 2,260 人开始时间: 2026年4月16日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Mayo Clinic
入组人数
2,260
试验地点
3
主要终点
Hospital-Free Days

研究概览

简要总结

The purpose of this study is to determine the effect of a multidisciplinary intervention at care transitions for acute kidney injury survivors on patient-centered outcomes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinician subjects
  • Hospital clinicians including physicians and advanced practice providers employed by Mayo Clinic and practicing at one of the four study sites
  • Provide care for hospitalized patients with stage 2 or stage 3 acute kidney injury (AKI) who are expected to be discharged home and are not receiving dialysis
  • Patient subjects:
  • Adults ≥18 years old
  • Meet KDIGO consensus criteria for stage 2 (moderate) or 3 (severe) AKI
  • Residence within the study catchment area (southern Minnesota, northern Iowa, or western Wisconsin)

排除标准

  • Clinician subjects: Physicians and advanced practice providers who:
  • Care exclusively for pediatric patients (<18 years)
  • Care exclusively for patients on palliative care
  • Patient subjects
  • Discharged to hospice care
  • Require outpatient dialysis at discharge
  • Are admitted from or expected to be discharged to a skilled nursing facility
  • Dementia Diagnosis
  • Have undergone solid organ transplant within the past 100 days
  • Decline authorization for use of their medical records for research

结局指标

主要结局

Hospital-Free Days

时间窗: 90 days, 180 days, 1 year

Hospital-free days is defined as the total number of days a patient is alive and out of the hospital within the specified time frame.

次要结局

  • Unplanned hospital readmissions or acute care contact or death(90-days, 180-days, 1 year)
  • Death(90-days, 180-days, 1-year)
  • AKI recurrence(90 days, 180 days, 1 year)
  • Major Adverse Kidney Event(90-, 180- days)
  • Change in Estimated Glomerular Filtration Rate (eGFR) from preadmission baseline(90 days, 180 days, 1 year)
  • Chronic kidney disease (CKD)(90 days, 180 days, 1 year)
  • End-stage kidney disease (ESKD)(90 days, 180 days, 1 year)
  • Kidney transplantation(90 days, 180 days, 1 year)
  • Major adverse cardiovascular event(90-days, 180-days, 1 year)
  • Provider and laboratory follow-up(30-days, 90-days, 180-days)
  • Post-discharge serum creatinine evaluation(time to first, 30-days, 90-days, 180-days)
  • Post-discharge urine protein evaluation(time to first, 30-days, 90-days, 180-days)
  • Primary care follow-up(time to first, 30-days, 90-days, 180-days)
  • Nephrology follow-up(time to first, 30-days, 90-days, 180-days)
  • Pharmacist follow-up(time to first, 30-days, 90-days, 180-days)
  • Guideline concordant care(90 days, 180 days, 1 year)
  • Engaged in remote monitoring program (RPM) program(30 days, 90 days)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Erin Barreto

Principal Investigator

Mayo Clinic

研究点 (3)

Loading locations...

相似试验